Takeda Pharmaceutical Co. of Japan made a fourth offer Friday to buy Shire PLC, raising its bid slightly to about $62 billion, according to Shire, the second-largest biotech employer in Massachusetts.
Shire said its board was considering the offer and “will issue a further announcement in due course.”
Takeda has made three offers to buy Shire since March 28, when the company said it was making a play for the Irish-based firm, which has most of its operations in Lexington. But Shire rejected all three. The last one totaled about $61 billion.
Shire has more than 3,000 workers in Massachusetts and specializes in medicines for rare diseases, as well as the ADHD drug Adderall. The company’s board said it rejected the third offer unanimously because it “continues to significantly undervalue the company and Shire’s growth prospects and pipeline.”Jonathan Saltzman
can be reached at email@example.com